Johnson & Johnson (JNJ) Q2 2026 — sales $25.3B (+6.6% Y/Y) beat $25.05B est and adjusted EPS $2.90 beats $2.85 est on Innovative Medicine +7.8%; FY26 guidance raised to <meta name="viewport" content="width=device-width, initial-scale=1.0" />01.1B sales and <meta name="viewport" content="width=device-width, initial-scale=1.0" />1.68 adj EPS (midpoints) — company on track for first <meta name="viewport" content="width=device-width, initial-scale=1.0" />00B+ revenue year in 140-year history

01.1B midpoint — on track for its first 00B+ year." /> 01.1B sales and 1.68 adj EPS (midpoints) — company on track for first 00B+ revenue year in 140-year history" /> 01.1B midpoint — on track for its first 00B+ year." /> 01.1B sales and 1.68 adj EPS (midpoints) — company on track for first 00B+ revenue year in 140-year history" /> 01.1B midpoint — on track for its first 00B+ year." />

Stock/TLDR — What Just Moved Markets: Earnings, Fed, M&A, MoversA high-volume feed of market-moving releases — quarterly earnings, FOMC decisions, M&A, regulatory actions, big single-name moves, macro prints, commodities and crypto — refreshed every 12 hours. Each release is explained in plain English so you actually understand what just happened and which tickers it touches.This site uses JavaScript to render the interactive feed. Enable JavaScript to use it.Stock/TLDR is not investment advice. Verify everything against primary sources before trading.